SMI 11?817 -1.0%  SPI 15?339 -1.0%  Dow 34?798 0.1%  DAX 15?532 -0.7%  Euro 1.0824 -0.1%  EStoxx50 4?159 -0.9%  Gold 1?750 0.4%  Bitcoin 39?725 -4.3%  Dollar 0.9257 0.2%  Öl 78.0 1.0% 

Neustart mit "frischem Kapital"

Seite 7 von 10
neuester Beitrag: 21.09.21 23:57
eröffnet am: 10.01.15 03:05 von: Heron Anzahl Beiträge: 231
neuester Beitrag: 21.09.21 23:57 von: RichyBerlin Leser gesamt: 63683
davon Heute: 15
bewertet mit 4 Sternen

Seite: Zurück 1 | 1 | 2 | 3 | 4 | 5 | 6 |
| 8 | 9 | ... Weiter  

17.01.19 21:57
1

9812 Postings, 4918 Tage RichyBerlinDa springt sie ..

 
Angehängte Grafik:
agen_2019-01-17.png (verkleinert auf 30%) vergrößern
agen_2019-01-17.png

18.01.19 13:23

4395 Postings, 6037 Tage martin30smGehts heute schon auf 4 Dollar rauf?

29.01.19 14:36

4395 Postings, 6037 Tage martin30smNews

Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.
Dienstag, 29.01.2019 14:05 von PR Newswire

   
PR Newswire

NEW YORK, Jan. 29, 2019

NEW YORK, Jan. 29, 2019 /PRNewswire/ -- At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (NASDAQ: AGEN), announced the  launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Agenus' lead immuno-oncology asset. The proceeds from the digital securities offering, the first conducted by a publicly-traded company, will go to fund product development through FDA approval and commercialization, of the asset, with returns to investors backed by future product sales.

"Atomic Capital is deeply committed to leveraging the transformative capabilities of Distributed Ledger Technology in the pursuit of our mission to make capital smarter."  said Alexander S. Blum, CEO of Atomic Capital. "We are privileged to be working alongside Dr. Armen and his remarkable team, bringing precision capital to precision medicine."

Digital securities built on a distributed ledger use smart contracts to enforce compliance and investor protection while also providing access to secondary liquidity via 24/7 global markets.


Anzeige
Investieren wie die Experten mit dem FuW-Risk-Portfolio Index
Seit 1995 gibt die «Finanz und Wirtschaft» direkte Anlageempfehlungen innerhalb des Schweizer Aktienuniversums ab und veröffentlicht sie regelmässig im FuW-Risk-Portfolio mit dem Ziel, ein besseres Renditeprofil als der Swiss Performance Index® zu erreichen. Ab sofort kann man über Leonteq in den FuW-Risk-Portfolio Index investieren. Mehr »

powered by finative


"We are excited to be working with Atomic Capital, an innovator in emerging blockchain-based digital securities, in the launch of the first of its kind Biotech Electronic Security Token,"  said Garo Armen, PhD Chairman and CEO of Agenus.  "We believe this unique instrument will pave the way for allowing targeted investment by any qualified investor in the development of therapeutic drugs and has the potential to transform how drug development is financed."

Atomic Capital also announced this morning the launch of the digital securities offerings of two additional clients on their platform; a US-licensed, digital bank, and a blockchain-enabled digital AdTech company.

About Atomic Capital
Atomic Capital is a technology and financial group with a digital investment banking platform leveraging smart contracts and to automate the compliant offering, sale, and issuance of digital securities to investors. Atomic Capital delivers the core technology, global relationships, and industry experience to bring growth capital to exceptional investments across the infrastructure, software, and life sciences sectors. Atomic Capital is headquartered in New York City. For more information, visit www.atomiccapital.io and follow on Twitter at @Atomic_Capital.

About Agenus Inc
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and on twitter @agenus_bio.

Atomic Capital and its affiliates are licensed with LoHi Securities, A Registered Broker-Dealer, Member FINRA/SIPC, 1888  Sherman Street, Suite 770 Denver, CO 80203 USA. 720-465-5305. LoHi Securities and Atomic Capital, Inc. are not affiliated entities.

Cision View original content:http://www.prnewswire.com/news-releases/...-agenus-inc-300785633.html

SOURCE Atomic Capital

 

13.02.19 16:08

4395 Postings, 6037 Tage martin30smDie Welle über 4 Dollar sollte kurz

bevorstehen....  

19.02.19 15:08

4395 Postings, 6037 Tage martin30smNews

Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare
Dienstag, 19.02.2019 14:35 von PR Newswire

 

PR Newswire

LEXINGTON, Mass., Feb. 19, 2019

LEXINGTON, Mass., Feb. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security Token (BEST), the first digital-security offering in healthcare.

Agenus Logo


Agenus will host a conference call and live audio webcast today at 11:00 a.m. ET to discuss the launch of BEST and provide a full briefing on the digital security and offering process.

Agenus previously announced that BEST is designed to be an innovative and transformative way to finance drug development by increasing liquidity, minimizing dilution, and improving capital allocation.  BEST is envisioned as a way to democratize financing through targeted investments for specific therapeutic drug products. Tokenization will enable accredited investors the opportunity to invest directly in a single asset, Agenus' anti-PD-1 antibody (AGEN2034), while preserving shareholder equity.

In this first phase of Agenus' security token offering, accredited investors will be eligible to subscribe for BESTs at a 40% discount to the $1.67 issue price until the closing date of March 12, 2019. Agenus reserves the right to limit the number of tokens that will be issued at this price. Oversubscribed amounts in this phase will be given priority in any subsequent stage of the offering.

BESTs are being offered by Agenus pursuant to a Private Placement Memorandum that can be found at https://helium.atomiccapital.io/agenus. Before you invest, you should read the Private Placement Offering Memorandum for more complete information about this offering. This release shall not constitute an offer to sell or the solicitation of an offer to buy BESTs, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

Conference Call & Webcast Information

Presentation Date and Time: February 19, at 11:00am (EST)
A live webcast & presentation will be accessible at: https://www.webcaster4.com/Webcast/Page/1556/29470  
Domestic Dial-in Number: 1-844-492-3727
International Dial-in Number: 1-412-317-5118
Conference ID: Agenus
Webcast will be also accessible from the "Events & Presentations" section of the Company's investor website at www.agenusbio.com. A replay will be available following the presentation.
Atomic Telegram Channel Discussion

Immediately following the Agenus teleconference, please join Garo Armen, CEO of Agenus Inc, and Alexander S. Blum, CEO of Atomic Capital, to hear more about the first offering of a digital security in healthcare, why Agenus is taking this innovative approach, and how to participate.

Event Date and Time: February 19, at 12:00PM (EST)
Access to the live online discussion will be available on the Atomic Capital Telegram Channel, located at https://t.me/joinchat/HTsC_xBqNhCHvPMZmuK0Mg.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

About BEST

Biotech Electronic Security Tokens (BESTs) are blockchain-based securities that will be issued in accordance with Regulation D of the Securities Act of 1933, which will entitle the holders to a portion of U.S. net sales of AGEN2034 until a defined multiple of the original purchase price is earned.

BEST holders will benefit from downside protection in the form of a conversion provision that may be exercised in the event that AGEN2034 does not receive FDA approval by a certain date.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated terms, timing and impact of Agenus' BEST offering, the ability for any accredited investor to purchase BESTs, and the potential approval and commercialization of AGEN2034. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as the Risk Factors included in the Private Placement Offering Memorandum dated as of February 19, 2019 pursuant to which BESTs will be issued. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:

Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

1Through AgenTus Therapeutics, a subsidiary of Agenus

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/...-healthcare-300797751.html

SOURCE Agenus  

20.02.19 18:12

4395 Postings, 6037 Tage martin30smWarum dieser Kurssturz?

13.03.19 13:37

4395 Postings, 6037 Tage martin30smAgenus Milestone Triggers 7,5M Payment from Gilead

Agenus Milestone Triggers $7.5M Payment from Gilead
Mittwoch, 13.03.2019 13:30 von PR Newswire

 

PR Newswire

LEXINGTON, Mass., March 13, 2019

LEXINGTON, Mass., March 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc. This milestone triggered a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments in 2019 and beyond.

Agenus Logo

"This marks the first milestones in our collaboration with Gilead," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "AGEN1423 is a first-in-class molecule which we designed to block mechanisms that tumors use to escape and grow; we believe that this molecule has great potential for patients with cancer."


Anzeige
4 - 6 % p.a. laufende Ausschüttung plus Wertsteigerung
Mit Exporo Bestand profitieren Sie gleich doppelt von einer bestehenden Immobilie. Wie ein Eigentümer erhalten Sie regelmäßige Ausschüttungen aus den Mietüberschüssen und sind am Wertzuwachs der Immobilie beteiligt. Mehr »

powered by finative


The collaboration between the two companies was announced in December 2018. Under the terms of the agreement, Agenus received $150 million in upfront cash payment and equity investment and is also eligible for approximately $1.7 billion in potential future fees and milestones. Gilead received worldwide exclusive rights to AGEN1423, and exclusive option to license two additional programs: AGEN1223 and AGEN2373. Agenus is responsible for developing the option programs up to the option decision points, at which time Gilead may acquire exclusive rights to the programs on option exercise. For one of the option programs, Agenus will have the right to opt-in to shared development and commercialization in the U.S. Gilead also received right of first negotiation for two additional, undisclosed preclinical programs.

AGEN1423, AGEN1223 and AGEN2373 are investigational agents that have not been approved for any uses. Efficacy and safety have not been established.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the potential benefits of AGEN1423, as well as future potential royalty and milestone payments from Gilead. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc.
Jennifer S. Buell, PhD 781-674-4420
jennifer.buell@agenusbio.com

1Through AgenTus Therapeutics, a subsidiary of Agenus

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/...from-gilead-300811643.html

SOURCE Agenus Inc.  

14.03.19 13:15

4395 Postings, 6037 Tage martin30smHeute kommen Zahlen für 2018

Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast
Freitag, 08.03.2019 15:00 von PR Newswire

 

PR Newswire

LEXINGTON, Mass., March 8, 2019

LEXINGTON, Mass., March 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, March 14, 2019. In connection with the earnings release, Agenus executives will host a conference call and live webcast at 8:30 a.m. ET the same day to discuss the results and provide Company updates.

Agenus Logo

Conference Call and Webcast Information:
Date: Thursday, March 14, 2019
Time: 8:30 a.m. ET
Domestic Dial-in Number: 1-844-492-3727
International Dial-in Number: 1-412-317-5118
Conference ID: Agenus


Anzeige
4 - 6 % p.a. laufende Ausschüttung plus Wertsteigerung
Mit Exporo Bestand profitieren Sie gleich doppelt von einer bestehenden Immobilie. Wie ein Eigentümer erhalten Sie regelmäßige Ausschüttungen aus den Mietüberschüssen und sind am Wertzuwachs der Immobilie beteiligt. Mehr »

powered by finative


Live Webcast: accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/29717

A replay will be available on the Company's website approximately two hours after the call and will remain available for 90 days.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

1 Through AgenTus Therapeutics, a subsidiary of Agenus

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/...and-webcast-300808784.html

SOURCE Agenus Inc.

 

14.03.19 13:33

4395 Postings, 6037 Tage martin30smZahlen

Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Donnerstag, 14.03.2019 13:05 von PR Newswire

 

PR Newswire

LEXINGTON, Mass., March 14, 2019

LEXINGTON, Mass., March 14, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the fourth quarter and full year of 2018.

Agenus Logo

"We are rapidly advancing with the discovery and clinical development of our innovative I-O agents," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "In the past year, we entered into an important partnership with Gilead, delivered 6 INDs, and confirmed benefit in the majority of patients treated with our lead CTLA-4 and PD-1 antibodies. Our next steps will target submission and commercial launch readiness for our first two antibodies."


Achievements
Strengthened balance sheet with the Gilead collaboration and payments from milestones achieved with Incyte and Merck
$150M payment from Gilead
$21.5M additional milestones for advancing LAG-3 (INCAGN02385), TIM-3 (INCAGN02390), ILT4 (MK-4830) and FDA acceptance of the IND for AGEN1423, licensed to Gilead
Advanced lead programs and reported clinical benefit in majority of patients across multiple solid tumors, including cervical cancer
Ongoing trials in cervical cancer are designed to support BLA via accelerated pathway
We plan to expand PD-1 development in additional indications
Advanced new discoveries, which will enter the clinic this year
Next-Gen CTLA-4, AGEN1181
First-in-class bispecific, AGEN1223 (a Gilead option program)
Revenues of GSK's Shingrix, containing our QS-21 Stimulon®, exceed $1Bn (USD)
Bill & Melinda Gates Foundation award Agenus ~$1M to develop novel technology for QS-21
AgenTus Cell Therapy Business:
2019 INDs are on track
Partnership and private financing discussions are underway
Fourth Quarter and Full Year 2018 Financial Results

We ended 2018 with a cash balance of $53 million followed by the $150 million received from Gilead in 2019.      

For the fourth quarter ended December 31, 2018, we reported a net loss of $49 million or $0.40 per share compared to a net loss for same period in 2017 of $35 million, or $0.35 per share. In the fourth quarter, we recognized revenue of $6.5 million which includes non-cash royalties earned.

For the year ended December 31, 2018, we reported a net loss of $162 million or $1.44 per share compared to a net loss for the year ended 2017 of $121 million or $1.23 per share.  The increased net loss reflects reduced revenue during 2018 due to an accelerated milestone received during 2017 from Incyte, the 2018 loss on early extinguishment of debt and increased non-cash interest on our liability related to the sale of future royalties.

Conference Call, Webcast and Prepared Statement Information

Date: Thursday, March 14, 2019

Time: 8:30 a.m. ET

Domestic Dial-in Number: 1-844-492-3727

International Dial-in Number: 1-412-317-5118

Conference ID: Agenus

Live Webcast: accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/29717  

A replay will be available on the Company's website approximately two hours after the call and will remain available for 90 days.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

About AgenTus Therapeutics, Inc.

AgenTus Therapeutics, a subsidiary of Agenus, is a preclinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough "living drugs" to advance potential cures for cancer patients. AgenTus employs naturally-derived and engineered receptors, specifically T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs. AgenTus has locations in Lexington, MA and Cambridge, UK. For more information, please visit www.agentustherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus and AgenTus' clinical development and regulatory plans and timelines, the expectation for Agenus to become a commercial company and expanding beyond the initial targeted indication of cervical cancer and partnership and financing plans for AgenTus. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as the Risk Factors included in the Private Placement Offering Memorandum for BEST. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

1 Through AgenTus Therapeutics, a subsidiary of Agenus

Select Financial Information

(in thousands, except per share data)

(unaudited)








 

21.03.19 14:18
1

4395 Postings, 6037 Tage martin30smNews

Agenus Announces Clinical Appointments
Donnerstag, 21.03.2019 14:05 von PR Newswire

 

PR Newswire

LEXINGTON, Mass., March 21, 2019

LEXINGTON, Mass., March 21, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020.

Agenus Logo

Dr. Manuel Hidalgo, MD, PhD, joins as Strategic Advisor. Dr. Hidalgo, an internationally renowned oncologist, has led clinical development of more than 50 novel anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer. Dr. Hidalgo is the Director of Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center. He is also Co-Director of the Pancreas and Liver Institute, and Co-Director of the Pancreatic Cancer Research Program, at the Beth Israel Deaconess Medical Center (BIDMC). Dr. Hidalgo's groundbreaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer.


Anzeige
Dividenden: Verwöhnprogramm fu?r Aktionäre
ZÜRICH (COMMERZBANK) ? Rund um den Globus geben sich die Unternehmen derzeit spendabel. Eine starke Konjunktur und der auf Hochtouren laufende Gewinnmotor machen attraktive Dividendenzahlungen möglich. Zwar schwächte sich das Wachstum der Ausschüttungen derweil ab. Die hohen Dividendenrenditen sind dennoch ein starkes Argument für Aktien. Mehr »

powered by finative


Paulo Moreira was appointed as Global Head of Clinical Operations. Mr. Moreira joins Agenus from EMD Serono where, as the Head of Global Clinical Operations & External Innovation, he helped establish the company as a leader in patient centricity around clinical trials.

"I am thrilled to have Manuel and Paulo as part of our team to advance our innovative clinical programs," said Dr. Garo Armen, Chairman and CEO. "This is an exciting time at Agenus. Our lead PD-1 and CTLA-4 programs are in pivotal trials and our next generation anti-CTLA-4 and multiple other first-in-class programs are advancing towards the clinic this year."

Paulo joins Agenus from EMD Serono, where he served for 18 years in diverse positions within Clinical Development. He was named in PharmaVoice's 100 Most Inspirational Leaders in both 2015 and 2017, in recognition of his industry leadership in patient centricity and the advancement of clinical trials. More recently, he was recognized by CenterWatch as 2018 Top Innovator, for his work around the Clinical Trials Registry of the Future.

Agenus' clinical development team is led by industry veteran Dr. Anna Wijatyk, who has more than 20 years of experience in leading product approvals with the FDA, EMA and Health Canada.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding clinical development plans and timelines and the anticipated contributions of new team members. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

1Through AgenTus Therapeutics, a subsidiary of Agenus

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/...ppointments-300816271.html

SOURCE Agenus  

02.04.19 15:17

4395 Postings, 6037 Tage martin30smNews

Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
Dienstag, 02.04.2019 14:30 von PR Newswire

 

PR Newswire

LEXINGTON, Mass., April 2, 2019

LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells.

Agenus Logo

The first patient in the trial was dosed by Dr. Steven J. O'Day, M.D., Executive Director of the John Wayne Cancer Institute & Cancer Clinic, and a pioneer in delivering immune therapies to patients with cancer.  Dr. O'Day's pivotal work has led to the approvals of commercial antibodies targeting CTLA-4 and PD-1.  "AGEN1181 represents an important next-generation breakthrough with its potential for enhanced immune activation and tumor fighting abilities," said Dr. O'Day. "The pre-clinical data so far suggest that AGEN1181 may bring superior benefit compared to first generation anti-CTLA-4 antibodies and may be an optimal partner for combinations. I am thrilled to be working with this compound."


Anzeige
Schroders | Fintechs: 5 Schlüsseltrends für 2019
FRANKFURT (Schroders) ? Technologische Durchbrüche werden Finanzdienstleistungen von Grund auf verändern ? vom Umgang mit unseren persönlichen Finanzen bis hin zur disruptiven Bedrohung ganzer Bankinstitute. Das Tempo, in dem sich neue Technologie entwickelt und ausbreitet, wird nicht nachlassen. Mehr »

powered by finative


"AGEN1181 is a product of Agenus' innovation engine that has been key to rapidly delivering new discoveries to patients," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "AGEN1181 was developed based on a new mechanism of action discovered by our scientists. In addition to this monotherapy trial, we plan to pursue combination studies with AGEN1181 soon. Besides AGEN1181, additional important discoveries from our innovation engine are also advancing towards the clinic this year."

The Phase 1, open-label, multicenter study is designed to assess the maximum tolerated dose of AGEN1181 in subjects with advanced solid tumors. It will also evaluate the safety, tolerability, PK, and PD profiles and immunogenicity of this antibody. The outcome will determine the recommended phase II dose of AGEN1181.

AGEN1181 was developed based on a discovery made by Agenus scientists, that involves modification of a key region of an antibody, known as the "Fc region", to design next-generation, 'Fc engineered' antibodies that may significantly enhance functionality and antitumor immunity. To learn more about AGEN1181 and its potential advantages over first-generation anti-CTLA-4 antibodies, please see Agenus' Newsletter here.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding: the clinical utility of AGEN1181; expectations regarding the results of the Phase 1 study of AGEN1181; expectations for future clinical trial plans and development activities of AGEN1181; our clinical trial plans and activities, research and development plan and activities for antibodies other than AGEN1181; and the anticipated operations and benefits of AGEN1181 and our other programs. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:

Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

1 Through AgenTus Therapeutics, a subsidiary of Agenus

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/...-4-antibody-300822183.html

SOURCE Agenus Inc.  

22.08.19 12:42

4395 Postings, 6037 Tage martin30smNews

Agenus to Manufacture Clinical Supply of GS-1423 for Gilead
Invented by Agenus, licensed to Gilead, GS-1423 is a bi-functional antibody designed to block tumor escape mechanisms
Supply supports ongoing Phase 1 of GS-1423 in patients with advanced solid tumors
LEXINGTON, Mass., August 21, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced a manufacturing agreement with Gilead for the supply of GS-1423, a bi-functional molecule licensed to Gilead. This supply represents a second clinical batch for an ongoing Phase 1 clinical trial of GS-1423. Agenus is providing clinical supply at standard industry rates.

?Our state-of-the-art facility in Berkeley, California and experienced staff have delivered more than 50 antibodies into the clinic2,? said Al Dadson, Chief Manufacturing Officer of Agenus. ?In the last 18-20 months, we have set path-breaking records with the development and manufacture of 8 compounds including two bi-specific compounds with 7 accepted INDs and one pending acceptance.?

The collaboration between the two companies was announced in December 2018. Under the terms of the agreement, Agenus received $150 million in an upfront cash payment and equity investment and is eligible for approximately $1.7 billion in potential future fees and milestones.

GS-1423 is an investigational agent that has not been approved for any uses. Efficacy and safety have not been established.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy with combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary) and its proprietary cancer vaccine platforms. Agenus has a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus? clinical development, regulatory and manufacturing plans and timelines, as well as future potential royalty and milestone payments from Gilead. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc.
Jennifer S. Buell, PhD
781-674-4420
jennifer.buell@agenusbio.com

1 Through AgenTus Therapeutics, a subsidiary of Agenus
2 Inclusive of developments as part of XOMA

 

01.10.19 07:26

4395 Postings, 6037 Tage martin30smAgenus to Present at the Cantor Global Healthcare

Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
Montag, 30.09.2019 22:35 von PR Newswire  

 

PR Newswire

LEXINGTON, Mass., Sept. 30, 2019

LEXINGTON, Mass., Sept. 30, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that Jennifer Buell, PhD, Chief Operating Officer of Agenus, present an update on Agenus' progress and host one-on-one meetings with investors at the 2019 Cantor Global Healthcare Conference on October 4th, 2019 at the InterContinental New York Barclay Hotel.

Agenus Logo

The presentation will be webcast live and may be accessed by visiting the "Events & Presentations" page within the Investors section of the Agenus website www.agenusbio.com  or by using the link below. A replay of the webcast will be available on the Agenus website following the conference.

Anzeige
Was Anleger von Fondsmanagern erwarten
ZÜRICH (Schroders) ? Anleger halten die Umwelt und den Klimawandel für den Bereich, der die grösste Aufmerksamkeit der Fondsmanager erfordern sollte, wenn sie mit Unternehmen interagieren und ihr Verhalten beeinflussen. Dies zeigt die Global Investor Study, in der die Ansichten von mehr als 25.000 Anlegern weltweit erfasst wurden. Mehr »

powered by finative


Date: Friday, October 4, 2019

Time: 8:20 A.M. ET

Webcast: http://wsw.com/webcast/cantor10/agen/

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy with combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary) and its proprietary cancer vaccine platforms. Agenus has a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:
Agenus Inc.
Jennifer S. Buell, PhD
781-674-4420 jennifer.buell@agenusbio.com

1Through AgenTus Therapeutics, a subsidiary of Agenus



Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/...ober-4-2019-300928055.html

SOURCE Agenus  

04.11.19 13:25
1

4395 Postings, 6037 Tage martin30smZahlen

Agenus Provides Corporate Update with Third Quarter 2019 Financial Results
Montag, 04.11.2019 13:05 von PR Newswire  - Aufrufe: 11

 

PR Newswire

LEXINGTON, Mass., Nov. 4, 2019

LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a corporate update and reported financial results for the third quarter of 2019.

Agenus Logo

"We have made solid progress this year," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We expect clinical readouts from six separate antibody programs in 2020 as our robust pace continues. We expect to commence combo trials of our NexGen CTLA-4 with our own PD-1 this month. 2020 is expected to be an important year of data generation, substantial milestone payments and prudent collaborations for Agenus. We look forward to discussing these developments in more detail during our call and at our R&D day on November 15th."

Achievements
Delivered on partnership programs; received additional cash milestones
Received $22.5 million from Gilead as milestone payment for IND acceptances of AGEN1423 (now GS-1423), AGEN1223, & AGEN2373
CTLA-4 & PD-1 trials advance
2L cervical cancer trial designed to support BLA via accelerated pathway
Combination trial completes accrual and interim analysis
Monotherapy trial is on track to complete accrual and interim analysis by year-end
AGEN1181 (NexGen CTLA-4) trial advancing; combos with AGEN2034 (PD-1) to start
QS-21 Updates
Sales of Shingrix exceed $1Bn; eliminating HCR debt obligation and nearing milestone triggers of up to $40M
AgenTus Cell Therapy Business:
IND for AgenTus allogeneic cell therapy on track by year end; combos with Agenus check point antibodies planned in 2020
Partnership and private financing discussions are underway
Dr. Walter Flamenbaum appointed CEO of AgenTus
Third Quarter 2019 Financial Results

We ended the third quarter of 2019 with a cash balance of $93 million as compared to $53 million at December 31, 2018.

Cash used in operations for the quarter ended September 2019 was $28 million compared to $25 million for the same period in 2018. Cash provided by operations for the nine months ended September 2019 was $13 million as compared to cash used in operations of $95 million for the same period in 2018.

For the third quarter ended September 30, 2019, we reported net loss of $46 million or $0.33 per share compared to a net loss for same period in 2018 of $34 million, or $0.29 per share. For the nine months ended September 30, 2019, we reported a net loss of $81 million or $0.58 per share compared to a net loss for the same period in 2018 of $113 million or $1.04 per share.

During the nine months ended September 2019 we recognized revenue of $116 million which includes revenue from our transaction with Gilead and non-cash royalties earned.  This compares to revenue of $30 for the nine months ended September 2018.  Through the third quarter of 2019 we also recorded $30 million of non-cash interest expense due to our transaction with HCR related to the sale of future royalties.  

04.11.19 23:00

9812 Postings, 4918 Tage RichyBerlinAGEN - Chart

3 tolle Tage reichen leider noch nicht
 
Angehängte Grafik:
agen_2019-11-04.png (verkleinert auf 28%) vergrößern
agen_2019-11-04.png

06.11.19 22:45

4395 Postings, 6037 Tage martin30smSehr schöne Entwicklung :-)

08.11.19 07:48

4395 Postings, 6037 Tage martin30smWow, gestern von -10% noch ins Plus gedreht!

Das nenne ich Stärke!  

11.11.19 14:11

4395 Postings, 6037 Tage martin30smNews

Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
Montag, 11.11.2019 14:05 von PR Newswire  - Aufrufe: 7

 

PR Newswire

LEXINGTON, Mass., Nov. 11, 2019

LEXINGTON, Mass., Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with UroGen Pharma Ltd. Under the agreement Agenus is providing access to zalifrelimab (AGEN1884, anti-CTLA-4 antibody) for use with UroGen's sustained release technology for intravesical delivery in patients with urinary tract cancers.  Agenus is conducting clinical trials for zalifrelimab in combination with Agenus' anti-PD-1 antibody balstilimab (AGEN2034) for a planned BLA filing in cervical cancer. In addition, zalifrelimab is being evaluated as a monotherapy in PD-1 refractory patients.

Under the terms of the agreement, in addition to the $10 million upfront payment, Agenus is eligible to receive up to $200M in potential development, regulatory and commercial milestones, as well as 14-20% royalties on net sales.

"In our ongoing clinical trials, zalifrelimab and the combination of zalifrelimab plus balstilimab (AGEN2034, anti-PD-1 antibody) have delivered durable as well as curative responses in patients across a broad range of tumors.  Agenus is developing the combination in multiple solid tumors with a first planned BLA filing in 2020," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We are enthusiastic to expand the benefit of zalifrelimab through intravesical delivery to patients with urinary tract cancer in this exciting collaboration with UroGen."

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy with combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary) and its proprietary cancer vaccine platforms. Agenus has a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' clinical development and regulatory plans and timelines and the anticipated benefits of the UroGen collaboration.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

1Through AgenTus Therapeutics, a subsidiary of Agenus

Cision View original content:http://www.prnewswire.com/news-releases/...act-cancers-300955231.html

SOURCE Agenus Inc.  

18.11.19 21:05

89 Postings, 1490 Tage Berndthcdas läuft wie geschmiert

19.02.20 21:12

9812 Postings, 4918 Tage RichyBerlinAgenus an wichtiger Linie

 
Angehängte Grafik:
agenus_2020-02-19_21h.png (verkleinert auf 28%) vergrößern
agenus_2020-02-19_21h.png

27.02.20 12:26

9812 Postings, 4918 Tage RichyBerlinAgenus / seekingalpha-Artikel

"Conclusion
I think Agenus has very good prospects, but they are dependent on successful binary decisions to be made by the FDA. So it is not a stock for the risk-averse. A positive decision for the combination therapy in cervical cancer would open the door to label expansions in other forms of cancer. There is also the possibility of substantial milestone payments and royalties from Gilead, Incyte, and Merck. With the market meltdown from the coronavirus scare, the price is right to accumulate this stock..."
https://seekingalpha.com/article/...s-buy-for-cancer-therapy-pipeline
--
Und mein Chart;
 
Angehängte Grafik:
agenus_2020-02-26.png (verkleinert auf 28%) vergrößern
agenus_2020-02-26.png

29.05.20 22:55

9812 Postings, 4918 Tage RichyBerlinAgenus / ASCO

https://investor.agenusbio.com/...f-Agenus-AGEN1181-by-Dr-Steven-ODay
--
Im Chart hat sich seit Februar so einiges getan.. Der heutige Tag bringt endlich mal wieder richtig Speed nach oben
 
Angehängte Grafik:
agenus_2020-05-29.png (verkleinert auf 28%) vergrößern
agenus_2020-05-29.png

01.06.20 22:30

9812 Postings, 4918 Tage RichyBerlinAgenus

springt weiter.
Jetzt genau an der kleinen, roten Linie (s.Chartbild oben)
 

02.06.20 18:33

9812 Postings, 4918 Tage RichyBerlinAgenus/AgenTUS - Covid-19 !

https://investor.agenusbio.com/...KT-Cells-to-Treat-COVID-19-Patients
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
- AgenTus allogeneic iNKTs have potential to clear SARS-CoV-2 virus & mitigate harmful inflammation
- COVID-19 and cancer clinical trials to commence
- Dr. Koen van Besien at Weill Cornell/New York Presbyterian Hospital to lead COVID-19 trials
...
 

05.06.20 16:57

9812 Postings, 4918 Tage RichyBerlinAgenus-Chart

Also ich bin ja wirklich geduldig... aber Agenus nervt so langsam..
Die blaue Linie startet im Juni 2015... und selbst mit der "Covid-News" kommt der Kurs da nicht nachhaltig drüber !? grumpff...
 
Angehängte Grafik:
agenus_2020-06-05_1645h.png (verkleinert auf 28%) vergrößern
agenus_2020-06-05_1645h.png

Seite: Zurück 1 | 1 | 2 | 3 | 4 | 5 | 6 |
| 8 | 9 | ... Weiter  
   Antwort einfügen - nach oben

  9 Nutzer wurden vom Verfasser von der Diskussion ausgeschlossen: beegees06, BigSpender, s1893, Medipiss, nahkauf, hardylein, The_Uncecsorer, Robin, Tommy2015